Clinical Trial Update: A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing nivolumab to bevacizumab and evaluating nivolumab with or without ipilimumab in recurrent glioblastoma, with results posted in June 2022…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Recurrent Glioblastoma | Phase 3 | Status: COMPLETED | Results posted: 2022-06-29